Creative Planning Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Creative Planning increased its position in Arbutus Biopharma Co. (NASDAQ:ABUS) by 13.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,500 shares of the biopharmaceutical company’s stock after buying an additional 5,989 shares during the quarter. Creative Planning’s holdings in Arbutus Biopharma were worth $191,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in Arbutus Biopharma in the second quarter valued at $34,000. Walleye Trading LLC purchased a new stake in shares of Arbutus Biopharma during the 1st quarter valued at about $36,000. Helen Stephens Group LLC purchased a new stake in shares of Arbutus Biopharma during the 3rd quarter valued at about $50,000. XTX Topco Ltd bought a new position in shares of Arbutus Biopharma during the 2nd quarter valued at approximately $53,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Arbutus Biopharma by 22.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 6,649 shares during the period. Institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Stock Down 0.5 %

ABUS stock opened at $3.73 on Tuesday. The business’s fifty day simple moving average is $4.03 and its two-hundred day simple moving average is $3.59. Arbutus Biopharma Co. has a twelve month low of $1.70 and a twelve month high of $4.72. The firm has a market cap of $706.80 million, a price-to-earnings ratio of -8.91 and a beta of 1.92.

Analyst Ratings Changes

Several research firms have weighed in on ABUS. Jefferies Financial Group upped their price target on Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. StockNews.com upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 10th. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a research report on Thursday, November 7th. Chardan Capital increased their target price on Arbutus Biopharma from $4.00 to $4.50 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, JMP Securities increased their price target on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Arbutus Biopharma presently has a consensus rating of “Moderate Buy” and an average price target of $5.38.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.